Valor202020212022202320242025TTMGastos comerciales, generales y administrativos737.67 M759.38 M854.01 M937.29 M1.01 B1.15 B1.15 BInvestigación y desarrollo628.12 M628.79 M649.61 M746.77 M747.18 M921.93 M921.93 MBeneficio operativo-36.77 M-82.34 M149.56 M158.1 M484.21 M409.48 M409.48 MTotal de ingresos no operativos8.6 M12.29 M6.63 M30.64 M66.28 M68.8 M70.44 MGastos por intereses, netos de intereses capitalizados29.31 M15.34 M15.97 M17.34 M12.67 M10.9 M10.9 MIngresos no operativos, una vez deducidos los gastos por intereses-20.71 M-3.04 M-9.34 M13.3 M53.62 M57.91 M59.55 MIngresos/gastos extraordinarios———————Beneficio antes de impuestos-42.32 M-75.35 M149.58 M188.56 M541.76 M482.48 M482.48 MParticipación en los beneficios-6 000——————Impuestos-901.42 M-11.27 M8.02 M20.92 M114.9 M133.58 M133.58 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos997 K2.63 M2.04 M365 K-20.14 M4.41 M4.41 MBeneficio neto antes de actividades interrumpidas859.1 M-64.08 M141.56 M167.65 M426.86 M348.9 M348.9 MOperaciones suspendidas———————Beneficio neto859.1 M-64.08 M141.56 M167.65 M426.86 M348.9 M348.9 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas867.41 M-64.08 M141.56 M167.65 M434.19 M356.24 M356.24 MBeneficio básico por acción4.75-0.350.760.892.251.821.82Beneficio por acción diluido4.53-0.350.750.872.211.81.8Número medio de acciones ordinarias180.8 M182.85 M185.27 M187.83 M190.03 M191.79 M766.69 MAcciones diluidas191.68 M182.85 M188.96 M191.59 M196.71 M197.39 M782.99 MEBITDA68.41 M25.7 M251.53 M262.48 M580.64 M489.04 M489.04 MEBIT-36.77 M-82.34 M149.56 M158.1 M484.21 M409.48 M409.48 MCosto de los ingresos524.27 M470.51 M483.67 M514.85 M580.24 M717.44 M717.44 MOtros costes de producción75.61 M00——119.21 M—Amortización y depreciación (flujo de caja)105.17 M108.04 M101.97 M104.39 M96.43 M79.56 M79.56 M
BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.